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Summary The plasminogen activation cascade is involved in carcinogenesis. invasion and metastasis. In this
study plasminogen activators and their type I inhibitor were evaluated in colonic tissue from 19 patients with
familial adenomatous polyposis coli. an inherited disorder characterised by the presence of thousands of
adenomatous polyps in the colorectum which predispose to colorectal cancer. The conversion of normal-
appearing colonic mucosa to neoplastic tissue in these patients was associated With an increase in urokinase-
type plasminogen activator and plasminogen activator inhibitor type 1. accompanied by a decreased level of
tissue-type plasminogen activator. These observations are essentially similar to those found in solitary
adenomas and carcinomas of the colon. and illustrate the uniform involvement of the plasminogen activation
system in colorectal carcinogenesis.
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Tumonrgenesis is considered to be a multistep process
(Fearon and Vogelstein, 1990). Most human colorectal car-
cinomas arise from pre-existing benign adenomatous polyps
or adenomas: the adenoma-carcinoma sequence (Morson,
1962). The existence and availability of these recognisable
premalignant stages provide an opportunity to examine
human colorectal carcinogenesis and tumour progression.
Familial adenomatous polyposis coli (FAP) is a dominantly
inherited autosomal disorder, characterised by an early onset
of multiple adenomatous polyps in the colorecturm, which,
when untreated, will inevitably lead to colorectal car-
cinoma.
Cell migration and invasion during tumor progression
involve the temporary degradation of components of the
extracellular matrix and basement membrane by proteolytic
enzymes. Plasmin is a proteinase able to catalyse the break-
down of a broad range of extracellular matrix proteins. The
proteolytic activity of plasmin is controlled by a complex
cascade of interactions involving activators, receptors and
inhibitors (Dan0 et al., 1985; Vassalli et al., 1991). Tissue-
type and urokinase-type plasminogen activator convert the
inactive proenzyme plasminogen into active plasmin. Spora-
dic colorectal neoplasms are characterised by an increase in
urokinase-type plasminogen activator and plasminogen acti-
vator inhibitors and a decreased level of tissue-type plas-
minogen activator compared with normal reference tissue as
demonstrated biochemically, immunohistologically and by in
situ hybridisation (De Bruin et al.. 1988; Sier et al., 1991a;
Pyke et al., 1991a,b).
In the present study normal tissue, adenomatous polyps,
and carcinomas were collected from patients operated on
because of familial adenomatous polyposis coli. The contents
of plasminogen activators and inhibitor type 1 were deter-
mined in homogenates of the tissues with several techniques
and in adenomas related to the diameter, which was found in
other studies to be correlated with the onset of malignancy
(Vogelstein et al., 1988; Fearon and Vogelstein. 1990).
Patients, materials and methods
Patients
Three invasive carcinomas. one carcinoma in situ, 85 adeno-
matous polyps and 31 representative parts of normal-appear-
ing mucosa from various parts of the colon were included in
this study from 19 patients (nine men, ten women: mean age
26 years) undergoing colectomy for familial adenomatous
polyposis coli. Of all samples. adjacent fragments were histo-
logically evaluated by the pathologist to confirm the diag-
nosis and origin of the tissue. All tissues were immediately
frozen at -70'C until analysis.
Tissue extraction andprotein concentration
Tissue specimens were homogenised in I ml of 0.1% (v v)
Tween 80-0.1 M Tris-HCl (pH 7.5) per 60 mg of wet tissue
as described previously (De Bruin et al., 1987). Protein con-
centration of the supernatants was determined by the method
of Lowry et al. (1951).
Plasminogen activator activitY assay
Activities of urokinase-type plasminogen activator and tissue-
type plasminogen activator were measured by a spectro-
photometric enzyme activity assay as described previously
(Verheijen et al., 1982; De Bruin et al., 1987).
Enzvme-linked immunosorbent assays (ELISAs) for
plasminogen activators
The ELISA for urokinase-type plasminogen activator was
carried out according to Binnema et al. (1986). Rabbit anti-
urokinase-type plasminogen activator IgG was used as catch-
ing antibody and affinity-purified goat anti-urokinase-type
plasminogen activator IgG as detecting antibody. After
washing, an optimal dilution of donkey anti-goat IgG con-
jugated with alkaline phosphatase was added (2 h) and p-
nitrophenylphosphate was used as substrate. A nine-point
standard curve of high molecular weight urokinase-type plas-
minogen activator (0-3.3 ng ml-') was included in the
assay.
Tissue-type plasminogen activator antigen was measured
essentially as described by Rijken et al. (1984). Goat anti-
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tissue-type plasminogen activator was used as catching anti-
body, an anti-tissue-type plasminogen activator-horseradish
peroxidase conjugate as second antibody and 3,3',5,5'-tetra-
methylbenzidine was used as substrate. Absolute quantities of
tissue-type plasminogen activator antigen in the samples were
calculated from an eight-point standard curve of tissue-type
plasminogen activator (0-4 ng ml -).
ELISA for plasminogen activator inhibitor txpe I
Total plasminogen activator inhibitor type I antigen, i.e.
latent, active and complexed, was determined using the Tin-
telize PAI-I ELISA (Biopool, UmeA, Sweden) without prior
denaturation of the samples as described previously (Sier et
al., 1991b). In order to increase the sensitivity of the assay, in
particular for normal tissue samples, volumes of up to 80 tL
were used, resulting in a detection limit of 0.3 ngmlpi as
indicated by the manufacturer.
Zymographv
Tissue extracts were incubated for 1 h (2% SDS, 37C) to
induce activator activity in plasminogen activatorlinhibitor
complexes (Levin, 1983). Electrophoresis of the samples took
place on 10% polyacrylamide gels with sodium dodecyl sul-
phate (SDS-PAGE). Plasminogen activator activities were
visualised on agarose underlay gels containing plasminogen
and fibrin (Granelli-Piperno and Reich, 1978).
Statistical analysis
Results are given as means ± s.e.m. Differences between
group means were tested for significance using Student's
t-test with separate variance estimate if the standard devia-
tions were significantly different according to the F-test.
Correlations were evaluated using linear regression statistics.
Differences and correlations were considered significant when
P<0.05.
Results
Within the normal colon no significant differences in the
plasminogen activator levels were detected in relation to the
location of the tissue. Therefore, the mean value of the whole
colon per patient is given (n = 15).
The mean plasminogen activator levels, both activity and
antigen, in normal and neoplastic colonic tissue from patients
with polyposis coli are shown in Figure 1. Significant differ-
ences were found between normal mucosa and neoplastic
tissues for both plasminogen activators. Urokinase-type plas-
minogen activator levels were 2- to 4-fold increased and
tissue-type plasminogen activator levels were approximately
3-fold decreased in carcinomatous tissue compared with nor-
mal mucosa. In general. plasminogen activator levels in
homogenates of adenomatous polyps were in between normal
and carcinomatous tissue values. As expected, the calculated
ratio of the increased urokinase-type plasminogen activator
antigen concentration and the decreased tissue-type plas-
minogen activator antigen level in tumor tissue homogenates
was significantly increased in comparison with normal
mucosa (Table I). With respect to plasminogen activator
inhibitor type 1, normal mucosa and adenomas were found
to have low concentrations of this inhibitor compared with
the carcinomas (Table I).
Tissue-type plasminogen activator activity was found to
decrease with increasing size of the adenomas (R = -0.47,
P<0.0001), in line with the changes seen in the normal
mucosa-adenoma-carcinoma sequence (R = -0.58, P<
0.0001; Figure 2). Tissue-type plasminogen activator antigen
in adenomas showed a similar tendency in relation to the
diameter. Urokinase-type plasminogen activator and plas-
minogen activator inhibitor type 1 were not found to change
in parallel with the size of the adenomas (data not shown).
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Frwe 1 Activity and antigen of urokinase-type plasminogen
activator (a) and tissue-type plasminogen activator (b) in homo-
genates ofnormal-appearing colonic mucosa and neoplastic tissue
from patients with familial adenomatous polyposis coli (LI,
mIU mg-' protein; , ngmg-' protein) u-PA, urokinase-type
plasminogen activator; t-PA, tissue-type plasminogen activator.
Significance of difference from normal mucosa: *P<0.5;
**P<0(%05. Significance of difference from adenomatous polyp:
tP<0.05.
Table I Antigen ratio of urokinase-type plasminogen activator and
tissue-type plasminogen activator, and the level of plasminogen
activator inhibitor type I in normal-appearing mucosa and neoplastic
tissue from patients with familial adenomatous polyposis coti
Normalmucosa A.denoma Carcinoma
u-PA,t-PA 0.8±0.1 3.0± 0.7** 1 1.4 3.6t
antigen ratio (n= 15) (n= 84) (n=4)
PAI-I 0.2±0.1 0.3±0.0 1.2±0.3*
antigen (n = 3) (n = 24) (n = 4)
Significance ofdifferencefrom normal mucosa: *P<0.05: **P<0.005.
Significance of difference from adenoma: tP<0.05. u-PA, urokinase-
type plasminogen activator in ng mg- protein: t-PA, tissue-type
plasminogen activator in ng mg- protein; PAI-1, plasminogen
activator inhibitor type 1 in ng mg- protein.
The zymographic analysis gave similar results as the activity
and antigen assays, i.e. normal tissues and adenomas showed
strong lysis in the tissue-type plasminogen activator area,
whereas carcinomas and many adenomas were frequently
found to give strong urokinase-type plasminogen activator
lysis bands on the fibrin-containing underlays (Table II).
Complexes of plasminogen activators with their specific
inhibitors were rarely seen in normal tissue but regularly in
the neoplastic tissues.
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Tablk H Numberofstrong lysis bandsoftissue-ty pai n activator, urokinase-
type plaino activator and plasninogen acivator-inhibitor compexes, scored on
zymogaphk underlay gels of colonic tissue homogenates derived from patients with
familial nomtous polypsis cob
Normal Adom Adenom Adenoma
nucosa <0-5can >05-1.0an >1.0an Carcinoma
(n = 15) (n =49) (n = 20) (n = 13) (n =4)
t-PA 15 100% 49 100% 20 100% 13 100% 3 75%
u-PA 2 13% 17 35% 10 50% 6 46% 4 100%
Complexes 1 7% 6 12% 8 40% 2 15% 2 50%
t-PA, tissue-type plainogen activator, u-PA, urokinase-type plas activator,
Complexes, plasinogen activator-inhibitor complxes.
4000 R=-0.58
P< 0.0001
3000
0.
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Normal Adenoma Adenoma Adenoma Carcinoma
mucosa s0.5 cm >0.5-1.0 cm >1.0 cm
n=15 n=50 n=2.0 n=14 n=4
Flgwe 2 Distribution of the activity of tissue-type plaio
activator (t-PA) acording to size of adenomatous polyps from
patients with familial adenomatous cobl compared with normal-
appearuig mucosa and carcinomas of the same patients. Bars
indite mean values of the groups.
Neoplastic tissues from patients with familial adenomatous
polyposis coli were found to have high levels of urokinase-
type plaminogen activator and type 1 inhibitor, and decreas-
ed levels of tissue-type plasminogen activator compared with
normal-appearing colonic mucosa of the same patients. The
changes in neoplastic polypos issue were similar to those
found in our previous studies of patients with solitary
sporadic adenomas and carcinomas ofthe colon (De Bruin et
al., 1988; Sier et al., 1991b). Many in vitro studies have been
published on the contribution of urokinase-type plasminogen
activator in physiological processes. In addition to the pro-
teolytic capacity, urokinase is able to activate growth factors
such as hepatocyte growth factor and transforming growth
factor P, and to influence the proliferation of (tumor) cell
lines in an autocrine fashion (Kirchheimer et al., 1987; Sato
et al., 1990; Gelister et al., 1990). Furthermore, the expres-
sion of the urokinase-type sminogen activator has been
shown to be related to the cytoskeletal organisation of the
cell (Frixen and Nagamine, 1993; Lee et al., 1993). In a study
with 171 polyps from 20 FAP patients, large adenomas
(>0.5 cm) showed a higher level of cell proliferation than
smaller adenomas, with no difference in the grade of dys-
plasia between the two groups (Quirke et al., 1988). In our
study the urokinase-type plasinogen activator did not show
a correlation with the diameter of the adenomas, but the
decrease of tissue-type plasminogen activator in neoplasms
was found to be significantly correlated with increasing size
of the adenomas. This phenomenon was also observed in a
previous study with sporadic colonic adenomas (De Bruin et
al., 1988) and is probably caused by a change in vascularisa-
tion. In the present study the levels of plaminogen activator
inhibitor type 1 in neoplastic tissxs were found to be in-
cased and were accompanied by high moleular lysis zones
on zymograms of these homogenates, representing complexes
of activators and inhibitors. Plasminogen activator inhibitor
type I levels were also found to be enhanced in carcinomas
and solitary adenomatous polyps from the colon (Pyke et al.,
1991a; Sier et al., 1991b). The enhancement of the urokinase
pathway of plasminogen activation and of inhibitor type 1,
together with the decreased levels of tissue-type plasminogen
activator, could be associated with the disruption of the
cytoskeletal organisation within the neoplastic colonic cells
which have been shown to possess less organised cytoskeletal
structures (Friedman et al., 1985). Moreover, disruption of
the microfilament structure of cultured cells has been shown
to inhibit the production of tissue-type plasminogen activator
and to stimulate production of the urokinase-type plasmino-
gen activator, inhibitor type 1 and other proteinases
(Unemori and Werb, 1986; Botteri et al., 1990; Santell et al.,
1992).
Genesis of adenomatous polyps in polyposis coli is charac-
terised by increased cell proliferation, a process which is
closely related to cell migration and cell growth. The uro-
kinase-type plasminogen activator has been shown to be
involved in a great number of processes of this kind and is
also found to be present in increased amounts in colorectal
adenomas and carcinomas of patients with or without
polyposis coli. Further studies of the plasminogen activation
system in tissue from these patients, in which successive
stages of (pre)malignancy are present in one patient, could
make an important contribution to the understanding of the
mechanism of plasminogen activation in human colorectal
carcinogenesis.
The authors wish to thankr the departments of Surgery (Head:
Professor Dr OT Terpstra) and Pathology (Head: Professor Dr Ph J
Hoedemaeker) of the University Hospital Leiden, and Drs FCA Den
Hartog-Jager (drsed), JG Goedhard, D Overbosch and AIJ van
der Veer for ther assista in tissu colction. Drs JH Verheijen, G
Dooijewaard, PHA Quax and MM Heeding are acknowledged for
their tchnical asistance. We are also grateful to L Niepoth and M
Koster-de Vreese for typmg the manuscrpt This study was sup-
ported by a grant (IKW 89-9) from the Dutch Cancer Society
(KWF).
Refer m
BINNEMA DJ, VAN LERSEL JIL AND DOOUEWAARD G. (1986).
Quantitation of urokinase antigen in plasma and culture media
by use of an ELISA. Thromb. Res., 43, 569-577.
BOlTERI FM, BALLMER-HOFER K, RAJPUT B AND NAGAMINE Y.
(1990). Disruption of cytoskeletal structures results in the induc-
tion ofthe urokinase-type plainogen activator gene expression.
J. Biol. Chem., 265, 13327-13334.
DAN0 K, ANDREASEN PA, GR0NDAHL-HANSEN J, KRISTENSEN P,
NIELSEN IS AND SKRIVER L. (1985). Plasninogen activators,
tissue degradation, and 'cancer. Adv. Cancer Res., 44,
139-266.CFM Sier eta
DE BRUIN PAF, VERSPAGET HW, GRIFFIOEN G, NAP M, VERHEIJ-
EN JH AND LAMERS CBHW. (1987). Plasminog activator
activity and composition in human colorectal carcinomas. Fib-
rmnolysis, 1, 57-62.
DE BRUIN PAF, GRIFFIOEN G. VERSPAGET HW. VERHELEN JH.
DOOUEWAARD G. VAN DEN INGH HF AND LAMERS CBHW.
(1988). Plasminogen activator profiles in neoplastic tissues of the
human colon. Cancer Res., 48, 4520-4524.
FEARON ER AND VOGELSTEIN B. (1990). A genetic model for
colorectal tumorigenesis. Cell, 61, 759-767.
FRIEDMAN E, VERDERAME M, LIPKIN M AND POLLACK R.
(1985). Altered actin cytoskeletal patterns in two premalignant
stages in human colon carcinoma development. Cancer Res., 45,
3236-3242.
FRIXEN UH AND NAGAMINE Y. (1993). Stimulation of urokinase-
type plasminogen activator expression by blockage of E-cadherin-
dependent cell-cell adhesion. Cancer Res., 53, 3618-3623.
GELISTER JSK, BOULOS PB, GAFFNEY PJ, MAHMOUD M AND
LEWIN MR. (1990). The relationship of plasminogen activators
and oncogenes to tumour invasion. Eur. J. Surg. Oncol., 16,
54-59.
GRANELLI-PIPERNO A AND REICH E. (1978). A study of proteases
and protease-inhibitor complexes in biological fluids. J. Exp.
Med., 148, 223-234.
KIRCHHEIMER JC. WOJTA J. CHRIST G AND BINDER BR. (1987).
Proliferation of a human epidermal tumor cell line stimulated by
urokinase. FASEB J., 1, 125-128.
LEE JS, VON DER AHE D. KIEFER B AND NAGAMINE Y. (1993).
Cytoskeletal reorganization and TPA differently modify AP-1 to
induce the urokinase-type plasminogen activator gene in LLC-
PKI cells. Nucleic Acids Res., 21, 3365-3372.
LEVIN EG. (1983). Latent tissue plasminogen activator produced by
human endothelial cells in culture: evidence for an
enzyme-inhibitor complex. Proc. Nail Acad. Sci. USA, 80,
6804-6808.
LOWRY OH, ROSEBROUGH NJ. FARR AL AND RANDALL R. (1951).
Protein measurement with the folin phenol reagent. J. Biol.
Chem., 193, 265-275.
MORSON BC. (1962). Precancerous lesions of the colon and rectum.
Classification and controversial issues. JAMA, 179, 316-321.
PYKE C. KRISTENSEN P. RALFKIAER E. ERIKSEN I AND DAN0 K.
(1991a). The plasminogen activation system in human colon
cancer: messenger RNA for the inhibitor PAI-I is located in
endothelial cells in the tumor stroma. Cancer Res., 51,
4067-4071.
PYKE C, KRLSTENSEN P, RALFKIAER E. GR0NDAHL-HANSEN J,
ERIKSEN J, BLASI F AND DANO K. (1991b). Urokinase-type
plasminogen activator is expressed in stromal cells and its recep-
tor in cancer cells at invasive foci in human colon adenocar-
cinomas. Am. J. Pathol., 13, 1059-1067.
QUIRKE P. DIXON MF, DAY DW. FOZARD JBJ. TALBOT IC AND
BIRD CC. (1988). DNA aneuploidy and cell proliferation in
familial adenomatous polyposis. Gut, 29, 603-607.
RIIKEN DC, VAN HINSBERGH VWM AND SENS EHC. (1984). Quanti-
tation of tissue-type plasminogen activator in human endotheial
cell cultures by use of an enzyme immunoassay. Thromb. Res.,
33, 145-153.
SANTELL L, MAROTTI K, BARTFIELD NS. BAYNHAM P AND
LEVIN EG. (1992). Disruption of microtubules inhibits the
stimulation of tissue plasminogen activator expression and pro-
motes plasinogen activator inhibitor type I expression in
human endothelial cells. Exp. Cell Res., 201, 358-365.
SATO Y. TSUBOI R, LYONS R. MOSES H AND RIFKIN DB. (1990).
Characterization of latent TGF-beta by co-cultures of endothelial
cells and pericytes or smooth muscle cells: a self regulating
system. J. Cell Biol., 111, 757-763.
SIER CFM, FELLBAUM C. VERSPAGET HW, SCHMITT M, GRIF-
FIOEN G, GRAEFF H, HOFLER H AND LAMERS CBHW. (1991a).
Immunolocalization of urokinase-type plasminogen activator in
adenomas and carcinomas of the colorectum. Histopathology, 19,
231 -237.
SIER CFM. VERSPAGET HW. GRIFFIOEN G. VERHEUEN JH. QUAX
PHA, DOOUEWAARD G, DE BRUIN PAF AND LAMERS CBHW.
(1991b). Imbalance of plasminogen activators and their inhibitors
in human colorectal neoplasia. Implication of urokinase in colb-
rectal carcinogenesis. Gastroenterology, 101, 1522-1528.
UNEMORI EN AND WERB Z7 (1986). Reorganization of polymerized
actin: a possible trigger for induction of procollagenase in fibro-
blasts cultured in and on collagen gels. J. Cell Biol., 103,
1021-1031.
VASSALLI JD. SAPPINO AP AND BELIN D. (1991). The plasminogen
activator/plasmin system. J. Clin. Invest., K, 1067-1072.
VERHEIJEN JH, MULLAART E, CHANG GTG, KLUFT C AND WIJN-
GAARDS G. (1982). A simple, sensitive spectrophotometric assay
for extrinsic (tissue-type) plasminogen activator applicable to
measurements in plasma. Thromb. Haemost., 48, 266-269.
VOGELSTEIN B, FEARON ER, HAMILTON SR. KERN SE, PREIS-
INGER AC, LEPPERT M. NAKAMURA Y. WHITE R, SMITS AMM
AND BOS JL. (1988). Genetic alterations during colorectal-tumor
development. N. Engi. J. Med., 319, 525-532.